E7384
[D-Ala2, N-Me-Phe4, Gly5-ol]-Enkephalin acetate salt
≥97% (HPLC), μ-opioid receptors agonist
别名:
DAGO, DAMGO, Tyr-D-Ala-Gly-N-methyl-Phe-Gly-ol
登录查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C26H35N5O6
化学文摘社编号:
分子量:
513.59
MDL编号:
UNSPSC代码:
12352209
PubChem化学物质编号:
NACRES:
NA.32
产品名称
[D-Ala2, N-Me-Phe4, Gly5-ol]-Enkephalin acetate salt, ≥97% (HPLC)
方案
≥97% (HPLC)
储存温度
−20°C
SMILES字符串
CC(O)=O.C[C@@H](NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N(C)[C@@H](Cc2ccccc2)C(=O)NCCO
InChI
1S/C26H35N5O6.C2H4O2/c1-17(30-25(36)21(27)14-19-8-10-20(33)11-9-19)24(35)29-16-23(34)31(2)22(26(37)28-12-13-32)15-18-6-4-3-5-7-18;1-2(3)4/h3-11,17,21-22,32-33H,12-16,27H2,1-2H3,(H,28,37)(H,29,35)(H,30,36);1H3,(H,3,4)/t17-,21+,22+;/m1./s1
InChI key
XZZYKCKUDLGXJA-NJUGUJQKSA-N
基因信息
human ... OPRM1(4988)
mouse ... OPRM1(18390)
rat ... OPRM1(25601)
正在寻找类似产品? 访问 产品对比指南
Amino Acid Sequence
Tyr-Ala-Gly-Nme-Phe-Gly-ol
一般描述
[D-Ala2, N-Me-Phe4, Gly5-ol]-Enkephalin acetate salt or DAMGO is a full agonist of the μ-opioid receptor. μ-opioid receptor is encoded by the OPRM1 gene, which has a predominant expression in reward-processing areas of brain. It acts as a receptor for endogenous opioids such as β-endorphin, encephalin, as well as foreign opioids such as morphine, heroin, and methadone.
应用
[D-Ala2, N-Me-Phe4, Gly5-ol]-Enkephalin acetate salt or DAMGO has been used:
- for use as a positive control in the assay of G-protein activation with μ-opioid receptor, to assay the inhibition of cAMP inhibition by DAMGO
- for the determination of the suppression of contraction by opioid receptors
- to determine whether the peripheral application of DAMGO suppresses the hypertonic saline (HS)-induced masseter nociception in slightly anaesthetized rats
生化/生理作用
Enkephalin analog that is a selective agonist at μ-opioid receptors.
包装
Bottomless glass bottle. Contents are inside inserted fused cone.
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
个人防护装备
Eyeshields, Gloves, type N95 (US)
法规信息
涉药品监管产品
此项目有
Raza Qazi et al.
Nature biomedical engineering, 3(8), 655-669 (2019-08-07)
Both in vivo neuropharmacology and optogenetic stimulation can be used to decode neural circuitry, and can provide therapeutic strategies for brain disorders. However, current neuronal interfaces hinder long-term studies in awake and freely behaving animals, as they are limited in
Javier Llorente et al.
The European journal of neuroscience, 36(12), 3636-3642 (2012-09-26)
There is considerable controversy over whether μ-opioid receptor (MOPr) desensitization is homologous or heterologous and over the mechanisms underlying such desensitization. In different cell types MOPr desensitization has been reported to involve receptor phosphorylation by various kinases, including G-protein-coupled receptor
Frank J Meye et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 32(46), 16120-16128 (2012-11-16)
μ-Opioid receptors (MORs) in the ventral tegmental area (VTA) are pivotally involved in addictive behavior. While MORs are typically activated by opioids, they can also become constitutively active in the absence of any agonist. In the current study, we present
Mariana Spetea et al.
British journal of pharmacology, 174(15), 2444-2456 (2017-05-12)
The κ receptor has a central role in modulating neurotransmission in central and peripheral neuronal circuits that subserve pain and other behavioural responses. Although κ receptor agonists do not produce euphoria or lead to respiratory suppression, they induce dysphoria and
Jami L Saloman et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 36(42), 10769-10781 (2016-11-01)
Designer receptors exclusively activated by designer drugs (DREADDs) are an advanced experimental tool that could potentially provide a novel approach to pain management. In particular, expression of an inhibitory (Gi-coupled) DREADD in nociceptors might enable ligand-dependent analgesia. To test this
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持